Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 4/2017

01-04-2017 | Review Article

Extracellular vesicles and blood diseases

Author: Shosaku Nomura

Published in: International Journal of Hematology | Issue 4/2017

Login to get access

Abstract

Extracellular vesicles (EVs) are small membrane vesicles released from many different cell types by the exocytic budding of the plasma membrane in response to cellular activation or apoptosis. EVs disseminate various bioactive effectors originating from the parent cells and transfer functional RNA and protein between cells, enabling them to alter vascular function and induce biological responses involved in vascular homeostasis. Although most EVs in human blood originate from platelets, EVs are also released from leukocytes, erythrocytes, endothelial cells, smooth muscle cells, and cancer cells. EVs were initially thought to be small particles with procoagulant activity; however, they can also evoke cellular responses in the immediate microenvironments and transport microRNAs (miRNA) into target cells. In this review, we summarize the recent literature relevant to EVs, including a growing list of clinical disorders that are associated with elevated EV levels. These studies suggest that EVs play roles in various blood diseases.
Literature
1.
Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123:8–23.PubMedCrossRef
2.
3.
Nomura S. Microparticle and atherothrombotic diseases. J Atherscler Thromb. 2016;23:1–9.CrossRef
4.
Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13:269–88.PubMedCrossRef
5.
Warren BA, Vales O. The release of vesicles from platelets following adhesion to vessel walls in vitro. Br J Exp Pathol. 1972;53:206–15.PubMedPubMedCentral
6.
Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M, et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res. 2008;7:5157–66.PubMedPubMedCentralCrossRef
7.
Bastos-Amador P, Pérez-Cabezas B, Izquierdo-Useros N, Puertas MC, Martinez-Picado J, Pujol-Borrell R, et al. Capture of cell-derived microvesicles (exosomes and apoptotic bodies) by human plasmacytoid dendritic cells. J Leukoc Biol. 2012;91:751–8.PubMedCrossRef
8.
Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161–72.PubMedCrossRef
9.
Ratajezak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20:847–56.CrossRef
10.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.PubMedCrossRef
11.
Ciardiello C, Cavallini L, Spinelli C, Yang J, Reis-Sobreiro M, de Candia P, et al. Focus on extracellular vesicles: new frontiers of cell-to-cell communication in cancer. Int J Mol Sci. 2016;17:175–91.PubMedPubMedCentralCrossRef
12.
Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581–93.PubMedCrossRef
13.
14.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.PubMedCrossRef
15.
Nolte-’t Hoen E, Cremer T, Gallo RC, Margolis LB. Extracellular vesicles and viruses: are they close relatives? Proc Natl Acad Sci USA. 2016;113:9155–61.PubMedPubMedCentralCrossRef
16.
Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Cir Res. 2012;110:356–69.CrossRef
17.
Nomura S, Niki M, Nishizawa T, Tamaki T, Shimizu M. Microparticles as biomarkers of blood coagulation in cancer. Biomak Cancer. 2015;7:51–6.CrossRef
18.
Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost. 2004;91:146–54.PubMed
19.
Simak J, Gelderman MP, Yu H, Wright V, Baird AE. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost. 2006;4:1296–302.PubMedCrossRef
20.
Ederhy S, Di Angelantonio E, Mallat Z, Hugel B, Janower S, Meuleman C, et al. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation. Am J Cardiol. 2007;100:989–94.PubMedCrossRef
21.
Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol. 2004;124:376–84.PubMedCrossRef
22.
Wang JG, Geddings JE, Aleman MM, Cardenas JC, Chantrathammachart P, Williams JC, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012;119:5543–52.PubMedPubMedCentralCrossRef
23.
Huang ME, Leonard JN. A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extra Vesicles. 2016;5:31027.CrossRef
24.
Iraci N, Leonardi T, Gessler F, Vega B, Pluchino S. Focus on extracellular vesicles: physiological role and signalling properties of extracellular membrane vesicles. Int J Mol Sci. 2016;17:171.PubMedPubMedCentralCrossRef
25.
Alberro A, Sáenz-Cuesta M, Muñoz-Culla M, Mateo-Abad M, Gonzalez E, Carrasco-Garcia E, et al. Inflammaging and frailty status do not result in an increased extracellular vesicle concentration in circulation. Int J Mol Sci. 2016;17:1168.PubMedCentralCrossRef
26.
Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FP, Nieuwland R, Sturk A. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost. 2003;1:2434–43.PubMedCrossRef
27.
Garcia BA, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF. The platelet microparticle proteome. J Proteome Res. 2005;4:1516–21.PubMedCrossRef
28.
Smalley DM, Root KE, Cho H, Ross MM, Ley K. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost. 2007;97:67–80.PubMed
29.
Alvarez-Erviti, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011;29:341–5.PubMedCrossRef
30.
Baietti MF, Zhang Z, Mortier E, Melchior A, Degeest G, Geeraerts A, et al. Syndecan-synternin-ALIX regulates the biogenesis of exosomes. Nat Cell Biol. 2012;14:677–85.PubMedCrossRef
31.
Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteom. 2010;73:1907–20.CrossRef
32.
György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68:2667–88.PubMedPubMedCentralCrossRef
33.
Muhsin-Sharafaldine MR, Saunderson SC, Dunn AC, Faed JM, Kleffmann, McLellan AD. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget (in press).
34.
35.
Colombo M, Moita C, van Niel G, Kowai J, Vigneron J, Benaroch P, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci. 2013;126:5553–65.PubMedCrossRef
36.
37.
Jayachandran M, Miller VM, Heit JA, Owen WG. Mathodology for isolation, identification and characterization of microvesicles in peripheral blood. J Immunol Methods. 2012;375:207–14.PubMedCrossRef
38.
Lynch SF, Ludlam CA. Plasma microparticles and vascular disorders. Br J Haematol. 2007;137:36–48.PubMed
39.
Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell Med Med. 2009;13:454–71.CrossRef
40.
Gasser O, Hess C, Miot S, Deon C, Sanchez JC, Schifferti JA. Characterisation and properties of ectosomes released by human polymorphoneclear neutrophils. Exp Cell Res. 2003;285:243–57.PubMedCrossRef
41.
Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol. 2009;19:1875–85.PubMedPubMedCentralCrossRef
42.
Li B, Antonyak MA, Zhang J, Cerione RA. Rho A triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene. 2012;31:4740–9.PubMedPubMedCentralCrossRef
43.
Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematol Am Soc Hematol Educ Program. 2011;2011:51–61.
44.
Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113:1–11.PubMedCrossRef
45.
Black LV, Saunderson SC, Coutinho FP, Muhsin-Sharafaldine MR, Damani TT, Dunn AC, et al. The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles. Immunol Cell Biol. 2015;94:430–8.PubMedCrossRef
46.
Thery C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001;166:7309–18.PubMedCrossRef
47.
Bilyy RO, Shkandina T, Tomin A, Muñoz LE, Franz S, Antonyuk V. Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J Biol Chem. 2012;287:496–503.PubMedCrossRef
48.
Leventis PA, Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys. 2010;39:407–27.PubMedCrossRef
49.
Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood. 2004;104:2761–6.PubMedCrossRef
50.
Turiak L, Misjak P, Szabo TG, Aradi B, Paloczi K, Ozohanics O, et al. Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/C mice. J Proteom. 2011;74:2025–33.CrossRef
51.
Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009;69:5601–9.PubMedPubMedCentralCrossRef
52.
Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, et al. Large oncosome in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012;181:1573–84.PubMedPubMedCentralCrossRef
53.
Minciacchi VR, You S, Spinelli C, Morley S, Zandian M, Aspuria PJ, et al. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget. 2015;6:11327–41.PubMedPubMedCentralCrossRef
54.
Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost. 2001;85:639–46.PubMed
55.
Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007;97:425–34.PubMed
56.
Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999;10:201–10.PubMedCrossRef
57.
Khan MM, Hattori T, Niewiarowski S, Edmunds LHJr, Colman RW. Truncated and microparticle-free soluble tissue factor bound to peripheral monocytes preferentially activated factor VII. Thromb Haemost. 2006;95:462–8.PubMed
58.
Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158:277–87.PubMedCrossRef
59.
Barry OP, Praticò D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136–44.PubMedPubMedCentralCrossRef
60.
Mallat Z, Hugel B, Ohan J, Lesèche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 1999;99:348–53.PubMedCrossRef
61.
Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, et al. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res. 1998;91:297–304.PubMedCrossRef
62.
Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest. 1999;104:93–102.PubMedPubMedCentralCrossRef
63.
Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T, Fukuhara S. Activated platelets and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost. 2004;10:205–15.PubMedCrossRef
64.
Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197:1585–98.PubMedPubMedCentralCrossRef
65.
Del Conde I, Shrimpton CN, Thiagarajan P, López JA. Tissue-factor- bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604–11.PubMedCrossRef
66.
Steppich B, Mattisek C, Sobczyk D, Kastrati A, Schömig A, Ott I. Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. Thromb Haemost. 2005;93:35–9.PubMed
67.
Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood. 2005;105:1515–22.PubMedCrossRef
68.
Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.PubMedCrossRef
69.
Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–35.PubMedPubMedCentralCrossRef
70.
Clayton A, Turkes A, Dewitt S, Steadman R, Mason MD, Hallett MB. Adhesion and signaling by B cell-derived exosomes: the role of integrins. FASEB J. 2004;18:977–9.PubMed
71.
Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619–24.PubMedCrossRef
72.
Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011;71:3792–801.PubMedCrossRef
73.
Zeelenberg IS, van Maren WW, Boissonnas A, Van Hout-Kuijer MA, Den Brok MH, Wagenaars JA, et al. Antigen localization controls T cell-mediated tumor immunity. J Immunol. 2011;187:1281–8.PubMedCrossRef
74.
Tomasoni S, Longaretti L, Rota C, Morigi M, Conti S, Gotti E, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013;22:772–80.PubMedCrossRef
75.
Borges FT, Reis LA, Schor N. Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz J Med Biol Res. 2013;46:824–30.PubMedPubMedCentralCrossRef
76.
Chen TS, Lai RC, Lee MM, Choo AB, Lee CN, Lim SK. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010;38:215–24.PubMedCrossRef
77.
Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics. 2009;9:4997–5000.PubMedCrossRef
78.
Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397–422.PubMedCrossRef
79.
Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy. J Cell Biochem. 2010;111:488–96.PubMedCrossRef
80.
Kosaka N, Yoshioka Y, Hagiwara K, Tominaga N, Katsuda T, Ochiya T. Trash or Treasure: extracellular microRNAs and cell-to-cell communication. Front Genet. 2013;4:173.PubMedPubMedCentralCrossRef
81.
Ostenfeld MS, Jeppesen DK, Laurberg JR, Boysen AT, Bramsen JB, Primdal-Bengtson B. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res. 2014;74:5758–71.PubMedCrossRef
82.
Nomura S, Yanabu M, Kido H, Fukuroi T, Yamaguchi K, Soga T, et al. Antiplatelet autoantibody-related microparticles in patients with idiopathic (autoimmune) thrombocytopenic purpura. Ann Hematol. 1991;62:103–7.PubMedCrossRef
83.
Jy W, Horstmann LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119:334–45.PubMed
84.
Ahn YS, Horstman LL. Idiopathic thrombocytopenic purpura: pathophysiology and management. Int J Hematol. 2002;76(Suppl):123–31.PubMedCrossRef
85.
Fontana V, Jy W, Ahn ER, Dudkiewicz P, Horstman LL, Ducan R, et al. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res. 2008;122:599–603.PubMedCrossRef
86.
Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res. 2013;131:e59–63.PubMedCrossRef
87.
Alvarez Román MT, Fernández Bello I, Arias-Salgado EG, Rivas Pollmar MI, Jiménez Yuste V, Martín Salces M, et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost. 2014;112:65–72.PubMedCrossRef
88.
Frelinger AL 3rd, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, et al. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015;126:873–9.PubMedPubMedCentralCrossRef
89.
Tantawy AA, Matter RM, Hamed AA, Shams El Din El Telbany MA. Platelet microparticles in immune thrombocytopenic purpura in pediatrics. Pediatr Hematol Oncol. 2010;27:283–96.PubMedCrossRef
90.
Ichijo M, Ishibashi S, Ohkubo T, Nomura S, Sanjo N, Yokota T, et al. Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura. J Stroke Cerebrovasc Dis. 2014;23:587–9.PubMedCrossRef
91.
Naghama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity. 2001;33:85–94.CrossRef
92.
Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost. 2006;95:94–9.PubMed
93.
Nomura S, Yanabu M, Fukuroi T, Kido H, Kawakatsu T, Yamaguchi K, et al. Anti-phospholipid antibodies bind to platelet microparticles in idiopathic (autoimmune) thrombocytopenic purpura. Ann Hematol. 1992;65:46–9.PubMedCrossRef
94.
Nagahama M, Nomura S, Kanazawa S, Ozaki Y, Kagawa H, Fukuhara S. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity. 2003;36:125–31.PubMedCrossRef
95.
Dignat-George F, Camoin-Jau L, Sabatier F, Arnoux D, Anfosso F, Bardin N, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91:667–73.PubMed
96.
Vikerfors A, Mobarrez F, Bremme K, Holmström M, Ågren A, Eelde A, et al. Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus. 2012;21:802–5.PubMedCrossRef
97.
Willemze R, Bradford RL, Mooberry MJ, Roubey RA, Key NS. Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications. Thromb Res. 2014;133:187–9.PubMedCrossRef
98.
Breen KA, Sanchez K, Kirkman N, Seed PT, Parmar K, Moore GW, et al. Endothelial and platelet microparticles in patients with antiphospholipid antibodies. Thromb Res. 2015;135:368–74.PubMedCrossRef
99.
Martínez-Zamora MA, Tàssies D, Creus M, Reverter JC, Puerto B, Monteagudo J, et al. Higher levels of procoagulant microparticles in women with recurrent miscarriage are not associated with antiphospholipid antibodies. Hum Reprod. 2016;31:46–52.PubMedCrossRef
100.
Galli M, Grassi A, Barbui T. Platelet-derived microparticles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Haemost. 1996;75:427–31.PubMed
101.
Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol. 2001;112:81–90.PubMedCrossRef
102.
Karpman D, Ståhl AL, Arvidsson I, Johansson K, Loos S, Tati R, et al. Complement interactions with blood cells, endothelial cells and microvesicles in thrombotic and inflammatory conditions. Adv Exp Med Biol. 2015;865:19–42.PubMedCrossRef
103.
Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17.PubMedCrossRef
104.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.PubMedCrossRef
105.
Hughes M, Hayward CP, Warkentin TE, Horsewood P, Chorneyko KA, Kelton JG. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood. 2000;96:188–94.PubMed
106.
Kasthuri RS, Glover SL, Jonas W, McEachron T, Pawlinski R, Arepally GM, et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood. 2012;119:5285–93.PubMedPubMedCentralCrossRef
107.
Mullier F, Minet V, Bailly N, Devalet B, Douxfils J, Chatelain C, et al. Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis. Thromb Res. 2014;133:1068–73.PubMedCrossRef
108.
Levi M, Ten Cate H. Disseminated intravascular coagulations. N Eng J Med. 1999;341:586–92.CrossRef
109.
110.
Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94:975–9.PubMed
111.
Iba T, Thachil. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103:253–61.PubMedCrossRef
112.
Nomura S, Fujita S, Ozasa R, Nakanishi T, Miyaji M, Mori S, et al. Correlation between platelet activation markers and HMGB1 in DIC patients with hematologic malignancy. Platelets. 2011;22:396–7.PubMedCrossRef
113.
114.
Delabrache X, Boisramé-Helms J, Asfar P, Berger A, Mootien Y, Lavigne T, et al. Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensiv Care Med. 2013;39:1695–703.CrossRef
115.
Hellum M, Øvstebø R, Brusletto BS, Berg JP, Brandtzaeg P, Henriksson CE. Microparticle-associated tissue factor activity correlates with plasma levels of bacterial lipopolysaccharides in meningococcal septic shock. Thromb Res. 2014;133:507–14.PubMedCrossRef
116.
Matsumoto H, Yamakawa K, Ogura H, Koh T, Matsumoto N, Shimazu T. Enhanced expression of cell-specific surface antigens on endothelial microparticles in sepsis-induced disseminated intravascular coagulation. Shock. 2015;43:443–9.PubMedPubMedCentralCrossRef
117.
Delabranche X, Stiel L, Severac F, Galoisy AC, Mauvieux L, Zobairi F, et al. Evidence of NETosis in septic shock-induced disseminated intravascular coagulation. Shock (in press).
118.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;1(106):3699–709.CrossRef
119.
Ziakas PD, Poulou LS, Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol. 2008;6:347–53.PubMedCrossRef
120.
Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–6.PubMed
121.
Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003;111:235–8.PubMedCrossRef
122.
Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2004;125:804–13.PubMedCrossRef
123.
Kozuma Y, Sawahata Y, Takei Y, Chiba S, Ninomiya H. Procoagulant properties of microparticles released from red blood cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2011;152:631–9.PubMedCrossRef
124.
Weitz IC, Razavi P, Rochanda L, Zwicker J, Furie B, Manly D, et al. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012;130:361–8.PubMedCrossRef
125.
van Bijnen ST, Østerud B, Barteling W, Verbeek-Knobbe K, Willemsen M, van Heerde WL, et al. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab. Thromb Res. 2015;136:274–81.PubMedCrossRef
126.
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007;97:119–23.PubMed
127.
Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007;5:520–7.PubMedCrossRef
128.
Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol. 2009;22:61–9.PubMedCrossRef
129.
Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb Res. 2010;125:S89–91.PubMedCrossRef
130.
131.
Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 2006;66:11013–20.PubMedCrossRef
132.
Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, et al. Involvement of platelet-derived microparticles in tumor progression and thrombosis. Semin Oncol. 2014;41:346–58.PubMedCrossRef
133.
Kanazawa S, Nomura S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S. Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer. 2003;39:145–9.PubMedCrossRef
134.
Tseng CC, Wang CC, Chang HC, Tsai TH, Chang LT, Huang KT, et al. Levels of circulating microparticles in lung cancer patients and possible prognostic value. Dis Markers. 2013;35:301–10.PubMedPubMedCentralCrossRef
135.
Wang CC, Tseng CC, Hsiao CC, Chang HC, Chang LT, Fang WF, et al. Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer. Biomed Res Int. 2014;2014:173401.PubMedPubMedCentral
136.
Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93:633–44.PubMedPubMedCentralCrossRef
137.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRef
138.
139.
140.
Gostterman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.CrossRef
141.
Ambudkar SV, Sauna ZE, Gottesman MM, Szakacs G. A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends Pharmacol Sci. 2005;26:385–7.PubMedPubMedCentralCrossRef
142.
Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 2007;1775:237–62.PubMed
143.
Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.PubMedCrossRef
144.
Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia. 2009;23:1643–9.PubMedCrossRef
145.
Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J. 2012;26:420–9.PubMedCrossRef
146.
Jaiswal R, Luk F, Dalla PV, Grau GE, Bebawy M. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One. 2013;8:e61515.PubMedPubMedCentralCrossRef
147.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11:109–24.PubMedCrossRef
148.
de Souza PS, Cruz AL, Viola JP, Maia RC. Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type. Cancer Sci. 2015;106:60–8.PubMedCrossRef
149.
Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322:1861–5.PubMedCrossRef
150.
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215–24.PubMedPubMedCentralCrossRef
151.
Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood. 2009;113:3911–7.PubMedPubMedCentralCrossRef
152.
Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M, Molenaar PJ, Ten Cate H, Terpstra WE, et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost. 2011;9:223–6.PubMedCrossRef
153.
Tzoran I, Rebibo-Sabbah A, Brenner B, Aharon A. Disease dynamics in patients with acute myeloid leukemia: new biomarkers. Exp Hematol. 2015;43:936–43.PubMedCrossRef
154.
Huan J, Hornick NI, Shurtleff MJ, Skinner AM, Goloviznina NA, Roberts CT Jr, et al. RNA trafficking by acute myelogenous leukemia exosomes. Cancer Res. 2013;73:918–29.PubMedCrossRef
155.
Huan J, Hornick NI, Goloviznina NA, Kamimae-Lanning AN, David LL, Wilmarth PA, et al. Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes. Leukemia. 2015;29:2285–95.PubMedPubMedCentralCrossRef
156.
Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, Piersma SR, Knol JC, Pham TV, et al. Exosomes secreted by apoptosis-resistant acute myeloid leukemia (AML) blasts harbor regulatory network proteins potentially involved in antagonism of apoptosis. Mol Cell Proteom. 2016;15:1281–98.CrossRef
157.
Tzoran I, Rebibo-Sabbah A, Brenner B, Aharon A. PO-46—influence of extracellular vesicles derived from AML patients on stem cells and their microenvironment. Thromb Res. 2016;140(Suppl 1):S193.PubMedCrossRef
158.
Hornick NI, Huan J, Doron B, Goloviznina NA, Lapidus J, Chang BH, et al. Serum exosome MicroRNA as a minimally-invasive early biomarker of AML. Sci Rep. 2015;5:11295.PubMedPubMedCentralCrossRef
159.
Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res. 2011;110:19–42.PubMedCrossRef
160.
Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, et al. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget (in press).
161.
Wong TW, Kita H, Hanson CA, Walters DK, Arendt BK, Jelinek DF. Induction of malignant plasma cell proliferation by eosinophils. PLoS One. 2013;8:e70554.PubMedPubMedCentralCrossRef
162.
Furukawa Y, Kikuchi J. Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. Int J Hematol. 2016;104:104–281.CrossRef
163.
Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Martinez MC, Clere N, et al. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron. 2013;54–55:75–81.PubMedCrossRef
164.
Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014;5:5686–99.PubMedPubMedCentralCrossRef
165.
Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, et al. Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. J Proteom. 2016;136:89–98.CrossRef
166.
Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, et al. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239:162–73.PubMedCrossRef
167.
168.
Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115:1755–64.PubMedPubMedCentralCrossRef
169.
Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–3.PubMedCrossRef
170.
Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, Meraviglia S, et al. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer. 2012;130:2033–43.PubMedCrossRef
171.
Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R, et al. Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis. 2012;15:33–45.PubMedCrossRef
172.
Nomura S, Inami N, Kanazawa S, Iwasaka T, Fukuhara S. Elevation of platelet activation markers and chemokines during peripheral blood stem cell harvest with G-CSF. Stem Cells. 2004;22:696–703.PubMedCrossRef
173.
Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Urase F, et al. α4 integrin-positive microvesicles and SDF-1 in peripheral blood stem cell harvest. Bone Marrow Transplant. 2008;41:1071–2.PubMedCrossRef
174.
Baj-Kizyworzeka M, Majka M, Oratico D, Ratajczak J, Vilaire G, Kijowski J, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450–9.CrossRef
175.
Nomura S, Kanazawa S, Inami N, Kamitsuji Y, Uoshima N, Ishida H, et al. Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation. Transplant Immunol. 2006;15:247–53.CrossRef
176.
Nomura S, Ishii K, Inami N, Uoshima N, Ishida H, Yoshihara T, et al. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentration after stem cell transplantation. Transplant Immunol. 2007;18:115–21.CrossRef
177.
Majka M, Kijowski J, Lesko E, Gozdzik J, Zupanska B, Ratajczak MZ. Evidence that platelet-derived microvesicles may transfer platelet-specific immunoreactive antigens to the surface of endothelial cells and CD34+ hematopoietic stem/progenitor cells—implication for the pathogenesis of immune thrombocytopenias. Folia Histochem Cytobiol. 2007;45:27–32.PubMed
178.
Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by an horizontal transfer of mRNA. Blood. 2007;110:2440–8.PubMedCrossRef
179.
Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752–60.PubMedCrossRef
180.
Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int. 2010;78:838–48.PubMedCrossRef
181.
Zou X, Zhang G, Cheng Z, Yin D, Du T, Ju G, et al. Microvesicles derived from human Wharton’s Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Res Ther. 2014;5:40.PubMedPubMedCentralCrossRef
182.
Miura Y. Human bone marrow mesenchymal stromal/stem cells: current clinical applications and potential for hematology. Int J Hemarol. 2016;103:122–8.CrossRef
183.
Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. Stem cell-derived extracellular vesicles and immune-modulation. Front Cell Dev Biol. 2016;4:83.PubMedPubMedCentralCrossRef
184.
Fischer S, Cornils K, Speiseder T, Badbaran A, Reimer R, Indenbirken D, et al. Indication of horizontal DNA gene transfer by extracellular vesicles. PLoS One. 2016;11:e0163665.PubMedPubMedCentralCrossRef
185.
Nomura S, Ishii K, Kanazawa S, Inami N, Uoshima N, Ishida H, et al. Significance of elevation in cell-derived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant. 2005;36:921–2.PubMedCrossRef
186.
Nomura S, Ishii K, Inami N, Kimura Y, Uoshima N, Ishida H, et al. Evaluation of angiopoietin and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:766–74.PubMedCrossRef
187.
Morel O, Ohlmann P, Epailly E, Backouboula B, Zobairi F, Jesel L, et al. Endothelial cell activation contributes to the release of procoagulant microparticles during acute cardiac allograft rejection. J Heart Lung Transplant. 2008;27:38–45.PubMedCrossRef
188.
Meng Y, Kang S, Fishman DA. Lysophosphatidic acid stimulates fas ligand microvesicles release from ovarian cancer cells. Cancer Immunol Immunother. 2005;54:807–14.PubMedCrossRef
Metadata
Title
Extracellular vesicles and blood diseases
Author
Shosaku Nomura
Publication date
01-04-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2180-x

Other articles of this Issue 4/2017

International Journal of Hematology 4/2017 Go to the issue

Case Report

Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia

Original Article

Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation

Original Article

Bone marrow T-cell percentage: A novel prognostic indicator in acute myeloid leukemia

Original Article

Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs

Case Report

Primary autoimmune myelofibrosis: a case report and review of the literature

Original Article

A novel mutation in the fibrinogen Aα chain (Gly13Arg, fibrinogen Nanning) causes congenital dysfibrinogenemia associated with defective peptide A release
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits